ClinVar Miner

Submissions for variant NM_000492.4(CFTR):c.3700A>G (p.Ile1234Val)

dbSNP: rs75389940
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 16
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
CFTR2 RCV000007636 SCV000245876 pathogenic Cystic fibrosis 2017-03-17 reviewed by expert panel research
Mendelics RCV000007636 SCV000886213 pathogenic Cystic fibrosis 2018-11-05 criteria provided, single submitter clinical testing
CFTR-France RCV000007636 SCV001169356 pathogenic Cystic fibrosis 2018-01-29 criteria provided, single submitter curation
Clinical Genetics and Genomics, Karolinska University Hospital RCV001269696 SCV001449885 pathogenic not provided 2017-01-20 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV001269696 SCV001470500 pathogenic not provided 2020-04-17 criteria provided, single submitter clinical testing The best available variant frequency is uninformative because there are too few occurrences in population data. Found in at least one patient with expected phenotype for this gene. Conflicting predictions of the effect on the protein. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Assessment of experimental evidence suggests this variant results in abnormal protein function.
Baylor Genetics RCV000007636 SCV001523285 pathogenic Cystic fibrosis 2020-06-10 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
Invitae RCV000007636 SCV001586454 pathogenic Cystic fibrosis 2023-09-09 criteria provided, single submitter clinical testing This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1234 of the CFTR protein (p.Ile1234Val). RNA analysis indicates that this missense change induces altered splicing and likely results in the loss of 6 amino acid residue(s), but is expected to preserve the integrity of the reading-frame. This variant is present in population databases (rs75389940, gnomAD 0.0009%). This missense change has been observed in individual(s) with cystic fibrosis (PMID: 10605524, 11336127, 15698946, 15948195, 21909392, 25593612, 26096753). ClinVar contains an entry for this variant (Variation ID: 7215). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CFTR protein function. Experimental studies have shown that this missense change affects CFTR function (PMID: 15480987, 24556927, 25735457). Studies have shown that this missense change results in the activation of a cryptic splice site in exon 19 (PMID: 15480987, 24556927, 25735457). For these reasons, this variant has been classified as Pathogenic.
Mayo Clinic Laboratories, Mayo Clinic RCV001269696 SCV001713432 pathogenic not provided 2019-07-03 criteria provided, single submitter clinical testing
Ambry Genetics RCV000007636 SCV002624131 pathogenic Cystic fibrosis 2017-01-12 criteria provided, single submitter clinical testing The p.I1234V pathogenic mutation (also known as c.3700A>G), located in coding exon 22 of the CFTR gene, results from an A to G substitution at nucleotide position 3700. The isoleucine at codon 1234 is replaced by valine. This mutation is the second most common CF-causing mutation in the Middle East (Molinski SV et al. Genet Med. 2014;16(8):625-32). This alteration was first described in an individual who was diagnosed with cystic fibrosis (CF) at 2 years of age and also carried the p.F508del mutation (Claustres M et al. Hum Mutat. 1992;1(4):310-3). In a large cohort of individuals homozygous for this mutation, this mutation was associated with pancreatic sufficiency (Abdel Rahman H et al. Acta Paediatr. 2006;95(9):1066-9). An in vitro functional study using reverse transcriptase-PCR found this mutation activates a cryptic donor splice site and results in the deletion of six amino acids (p.I1234_R1239del); this deletion causes a primary defect in protein folding and processing, similar to p.F508del but less severe (Molinski SV et al. Genet Med. 2014;16(8):625-32). A later study confirmed the alternative splicing described, through both an ex vivo study of RNA levels in nasal and colon epithelial cells from a CF patient, and a minigene assay using BHK cells. Furthermore, functional analysis showed reduced chloride channel function by the mutant protein (Ramalho AS, J. Cyst. Fibros. 2016 Jan; 15(1):21-33). Based on the supporting evidence, p.I1234V is interpreted as a disease-causing mutation.
Revvity Omics, Revvity RCV001269696 SCV003826269 likely pathogenic not provided 2022-09-28 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000007636 SCV003844257 pathogenic Cystic fibrosis 2023-02-27 criteria provided, single submitter clinical testing Variant summary: CFTR c.3700A>G (p.Ile1234Val) results in a conservative amino acid change located in the ABC transporter-like, ATP-binding domain (IPR003439) of the encoded protein sequence. Several computational tools predict a significant impact on normal splicing: Four predict the variant creates a 5' donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing by activating a cryptic donor splice site 18bp upstream of the original donor splice site, resulting in deletion of six amino acids (Molinski_2014). The variant allele was found at a frequency of 4e-06 in 249440 control chromosomes. c.3700A>G has been reported in the literature in multiple individuals affected with Cystic Fibrosis (Example: Claustres_1992, Abdul Wahab_2014, Wei_2006, Sosnay_2013 etc.). These data indicate that the variant is very likely to be associated with disease. At least one publication reports significantly impaired CFTR function (Molinski_2014). 11 clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
PreventionGenetics, part of Exact Sciences RCV001831553 SCV004115658 pathogenic CFTR-related disorder 2023-01-04 criteria provided, single submitter clinical testing The CFTR c.3700A>G variant is predicted to result in the amino acid substitution p.Ile1234Val. This variant has been reported in numerous patients with cystic fibrosis or CFTR-associated phenotypes (Hirtz et al. 2004. PubMed ID: 15480987; Wei et al. 2006. PubMed ID: 16617247; Molinski et al. 2014. PubMed ID: 24556927; El Bar Aluma et al. 2020. PubMed ID: 32843167). Functional studies showed that this variant alters splicing by activating an alternative splice site leading to a deletion of six amino acids and impacts protein function (Hirtz et al. 2004. PubMed ID: 15480987; Molinski et al. 2014. PubMed ID: 24556927; Ramalho et al. 2016. PubMed ID: 25735457). This variant is reported in 0.00089% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/7-117267807-A-G). This variant is interpreted as pathogenic.
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center RCV000007636 SCV004805192 pathogenic Cystic fibrosis 2024-03-17 criteria provided, single submitter research
OMIM RCV000007636 SCV000027837 pathogenic Cystic fibrosis 1993-01-01 no assertion criteria provided literature only
Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City RCV000007636 SCV001133028 pathogenic Cystic fibrosis 2019-09-26 no assertion criteria provided clinical testing
Natera, Inc. RCV001831553 SCV002075868 pathogenic CFTR-related disorder 2017-03-17 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.